neutral
1h agoMajor drugmakers agree to price cuts under new White House affordability push
A group of leading U.S. and European pharmaceutical companies has reached agreements with President Donald Trump’s administration to voluntarily lower drug prices in the United States. The deals, signed by firms including Pfizer, Merck, Bristol Myers Squibb, Amgen, Gilead, Sanofi, and Novartis, link reduced prices to a three year exemption from proposed pharmaceutical specific tariffs, provided companies expand U.S. manufacturing.
CNBC• By Pooja Kumari
Explore:High Return Equity Mutual Fund
neutral
1h agoMajor drugmakers agree to price cuts under new White House affordability push
A group of leading U.S. and European pharmaceutical companies has reached agreements with President Donald Trump’s administration to voluntarily lower drug prices in the United States. The deals, signed by firms including Pfizer, Merck, Bristol Myers Squibb, Amgen, Gilead, Sanofi, and Novartis, link reduced prices to a three year exemption from proposed pharmaceutical specific tariffs, provided companies expand U.S. manufacturing.
CNBC• By Pooja Kumari
Explore:High Return Equity Mutual Fund
1 min read
60 words
Several major pharmaceutical companies agreed to cut U.S. drug prices in exchange for tariff relief, expanded domestic manufacturing, and participation in new direct-to-consumer pricing initiatives.
A group of leading U.S. and European pharmaceutical companies has reached agreements with President Donald Trump’s administration to voluntarily lower drug prices in the United States. The deals, signed by firms including Pfizer, Merck, Bristol Myers Squibb, Amgen, Gilead, Sanofi, and Novartis, link reduced prices to a three year exemption from proposed pharmaceutical specific tariffs, provided companies expand U.S. manufacturing.
A group of leading U.S. and European pharmaceutical companies has reached agreements with President Donald Trump’s administration to voluntarily lower drug prices in the United States. The deals, signed by firms including Pfizer, Merck, Bristol Myers Squibb, Amgen, Gilead, Sanofi, and Novartis, link reduced prices to a three year exemption from proposed pharmaceutical specific tariffs, provided companies expand U.S. manufacturing.
Dec 20, 2025 • 06:55